Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production

Table 2

Subject demographic data for subjects involved in the logistic modeling study. There were insufficient numbers of subjects taking diuretics or angiotensin II receptor blockers to allow meaningful comparisons.

	CCBs			ACE			Beta blockers
	Users	Matched; nonusers	All	Users	Matched; nonusers	All	Users	Matched; nonusers	All
	32	31	63	13	13	26	22	21	43
Initial age; (mean ± SEM y)	75.4 ± 1.2	75.4 ± 1.2	75.4 ± 0.8	77.5 ± 1.6	76.9 ± 1.7	77.2 ± 1.1	75.5 ± 1.7	76.1 ± 1.7	75.8 ± 1.2
Age/pseudoage at drug initiation (mean ± SEM y)	79.2 ± 1.3	78.8 ± 1.3	79.0 ± 0.9	81.1 ± 2.1	81.1 ± 1.6	81.1 ± 1.6	79.4 ± 1.8	79.4 ± 1.8	79.2 ± 1.2
% women	73.5	75.0	74.2	61.5	61.5	61.5	52.4	54.2	52.4
Baseline comorbidities; ( [%])
Heart attack	3 (9.4)	1 (3.2)	4 (6.4)	1 (7.7)	0 (0.0)	1 (4.0)	3 (13.6)	0 (0.0)	3 (7.0)
Hypertension	18 (56.3)	6 (20.0)	24 (38.71)	3 (23.1)	0 (0.0)	3 (12.0)	6 (27.3)	0 (0.0)	6 (14.0)
Diabetes	3 (9.4)	1 (3.2)	4 (6.4)	2 (15.4)	1 (8.3)	3 (12.0)	1 (4.5)	2 (9.5)	3 (7.0)
High cholesterol	5 (15.6)	3 (10.3)	8 (13.11)	1 (7.7)	0 (0.0)	1 (4.0)	4 (18.2)	1 (4.8)	5 (11.6)